Articles
De Charry F, Colomban O, You B, Ruffion A, Paparel P, Wilbaux M, Tod M, Freyer G, Perrin P. Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases. Clin Genitourin Cancer. 2015 Dec 18. pii: S1558-7673(15)00336-5. doi: 10.1016/j.clgc.2015.12.006. Abstract ICI
Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL, Wong ZW, Salar A, Steger G, Abdelsalam M, DeCosta L, Szabo Z. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. Med Oncol. 2015 Oct;32(10):236. Abstract ICI
Rhondali W, Freyer G, Adam V, Filbet M, Derzelle M, Abgrall-Barbry G, Bourcelot S, Machavoine JL, Chomat-Neyraud M, Gisserot O, Largillier R, Le Rol A, Priou F, Saltel P, Falandry C. Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer. Clin Interv Aging. 2015 Jul 13; 10:11 55-62. Abstract ICI
Bourmaud A, Henin E, Tinquaut F, Regnier V, Hamant C, Colomban O, You B, Ranchon F, Guitton J, Girard P, Freyer G, Tod M, Rioufol C, Trillet-Lenoir V, Chauvin F. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods. BMC Res Notes. 2015 Jul 4;8:291. Abstract ICI
El-Madani M, Hénin E, Lefort T, Tod M, Freyer G, Cassier P, Valette PJ, Rodriguez-Lafrasse C, Berger F, Guitton J, Lachuer J, Slimane K, Barrois C, You B. Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations - example of EVESOR trial. Future Oncol. 2015 May; 11(10):1511-8. Abstract ICI
Goutelle S, Tod M. Quantitative methods for prediction of the effect of cytochrome P450 gene polymorphisms on substrate drug exposure. Clin Pharmacokinet. 2015 Mar; 54(3):319-20. Abstract ICI
Julien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, Pons G. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. Clin Pharmacokinet. 2015 May; 54(5):527-36. Abstract ICI
Sarfati L, Ranchon F, Vantard N, Schwiertz V, Gauthier N, He S, Kiouris E, Gourc-Berthod C, Guédat MG, Alloux C, Gustin MP, You B, Trillet-Lenoir V,Freyer G, Rioufol C. Simmeon-Prep study: SIMulation of Medication Errors in ONcology: prevention of antineoplastic preparation errors. J Clin Pharm Ther. 2015 Feb; 40(1):55-62. Abstract ICI
Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M,Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs. 2015 Feb; 33(1):257-68. Abstract ICI
Machon C, Bordes C, Cros-Perrial E, Clement Y, Jordheim LP, Lanteri P, Guitton J. Use of designed experiments for the improvement of pre-analytical workflow for the quantification of intracellular nucleotides in cultured cell lines. J Chromatogr A. 2015 Jul 31; 1405:116-25. Abstract ICI
Carlier J, Guitton J, Moreau C, Boyer B, Bévalot F, Fanton L, Habyarimana J, Gault G, Gaillard Y. A validated method for quantifying hypoglycin A in whole blood by UHPLC-HRMS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:70-7. Abstract ICI
Carlier J, Guitton J, Romeuf L, Bévalot F, Boyer B, Fanton L, Gaillard Y. Screening approach by ultra-hight performance liquid chromatography-tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to forensic toxicology. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 15;975 :65-76. Abstract ICI
Ranchon F, Vial T, Rioufol C, Hénin E, Falandry C, Freyer G, Trillet-Lenoir V, Le Tourneau C, You B. Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials. Crit Rev Oncol Hematol. 2015 May; 94(2):189-200. Abstract ICI
Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, You B, Souquet PJ, Freyer G, Salles G, Trillet-Lenoir V, Rioufol C. EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther. 2015 Apr; 40(2):196-203. Abstract ICI
Ranchon F, Boespflug A, Rioufol C, Schwiertz V, Thomas L, Dalle S. New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies. Anticancer Agents Med Chem. 2015; 15(4):461-7. Abstract ICI
Viel S, Garnier L, Joly E, Rouzaire P, Nosbaum A, Pralong P, Faudel A, Rioufol C, Bienvenu F, Bienvenu J, Berard F. The Basophil Activation Test: A Sensitive Test in the Diagnosis of Allergic Immediate Hypersensitivity to Pristinamycin. Int Arch Allergy Immunol. 2015 Jul 22;167(2):94-98. Abstract ICI
Kauffenstein G, Pizard A, Le Corre Y, Vessières E, Grimaud L, Toutain B, Labat C, Mauras Y, Gorgels TG, Bergen AA, Le Saux O, Lacolley P, Lefthériotis G, Henrion D, Martin L. Disseminated arterial calcification and enhanced myogenic response are associated with abcc6 deficiency in a mouse model of pseudoxanthoma elasticum. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1045-56. doi: 10.1161/ATVBAHA.113.302943. Epub 2014 Mar 27. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):e16. Abstract ICI
Le Saux O, Ripamonti B, Bruyas A, Bonin O, Freyer G, Bonnefoy M, Falandry C. Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging. 2015 Jan 6; 10:157-74. Abstract ICI
Ezzalfani M, Dugué A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Médioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X. [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. Bull Cancer. 2015 Jan; 102(1):73-82. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
LE SAUX Olivia, YOU Benoît, HENIN Emilie, PIERRILLAS Philippe, PERRIN Paul, RUFFION Alain, BONIOL Mathieu, FREYER Gilles, TOD Michel, COLOMBAN Olivier. Development and validation of a model of PSA kinetics predicting prostate cancer aggressiveness during screening. PAGE 24 (2015). Abstract 3428 ICI
Pierrillas Philippe, Tod Michel, Amiel Magali, Hénin Emilie. Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: a novel method to handle the interval-censoring caused by experimental measurement on smaller tumors. PAGE 24 (2015).
Abstract 3506 ICI
Articles
Loue C, Tod M. Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data. AAPS J. 2014 Nov;16(6):1309-20. Abstract ICI
Falandry C, Bonnefoy M, Freyer G, Gilson E. Biology of cancer and aging: a complex association with cellular senescence. J Clin Oncol. 2014 Aug 20;32(24):2604-10. Abstract ICI
Freyer G, You B, Villet S, Tartas S, Fournel-Federico C, Trillet-Lenoir V, Hamizi S, Colomban O, Chavernoz N, Falandry C. Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer. Homeopathy. 2014 Oct;103(4):232-8. Abstract ICI
Chabannon C, Bougnoux P, Favre G, Formstecher P, Laurent-Puig P, Oudet P, Trillet-Lenoir V. [Reply to « Why is it difficult to implement biomedical policy? The ase of the Canceropôles, the French cancer organizations », by Audrey Vézian, Med Sci (Paris) 2014 Aug-Sep; 30 (8-9) : 803-7. Abstract ICI
Falandry C, Krakowski I, Curé H, Carola E, Soubeyran P, Guérin O, Freyer G. Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey. Anticancer Res. 2014 Sep;34(9):5007-15. Abstract ICI
Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, Maurice C, Vaudoyer D, Gilly FN, Cotte E, Glehen O. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014 Aug;21(8):2608-14. Abstract ICI
Rioufol C, Salles G. Obinutuzumab for chronic lymphocytic leukemia.
Expert Rev Hematol. 2014 Oct;7(5):533-43. Abstract ICI
Matanza D, Hallouard F, Rioufol C, Fessi H, Fraysse M. Improving radiopharmaceutical supply chain safety by implementing bar code technology. Nucl Med Commun. 2014 Nov;35(11):1179-87. Abstract ICI
Lalande L, Charpiat B, Leboucher G, Tod M. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet. 2014 Jun;53(6):521-32. Abstract ICI
Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M. Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J. 2014 May;16(3):379-91. Abstract ICI
Breton AL, Pralong P, Trillet-Lenoir V, Balme B, Nicolas JF, Berard F. Disseminated porokeratosis transiently healed by cancer chemotherapy. Eur J Dermatol. 2014 Apr 1;24(2):260-1. Abstract ICI
Ranchon F, You B, Salles G, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guédat MG, Souquet PJ, Freyer G, Trillet-Lenoir V, Rioufol C. Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences. Chemotherapy. 2014 Apr 30;59(5):330-337. Abstract ICI
Bévalot F, Bottinelli C, Cartiser N, Fanton L, Guitton J. Quantification of five compounds with heterogeneous physicochemical properties (morphine, 6-monoacetylmorphine, cyamemazine, meprobamate and caffeine) in 11 fluids and tissues, using automated solid-phase extraction and gas chromatography-tandem mass spectrometry. J Anal Toxicol. 2014 Jun;38(5):256-64. Abstract ICI
Machon C, Jordheim LP, Puy JY, Lefebvre I, Dumontet C, Guitton J. Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2014 May;406(12):2925-41. Abstract ICI
Carlier J, Escard E, Péoc'h M, Boyer B, Romeuf L, Faict T, Guitton J, Gaillard Y. Atropine eye drops: an unusual homicidal poisoning. J Forensic Sci. 2014 May;59(3):859-64. Abstract ICI
Machon C, Le Calve B, Coste S, Riviere M, Payen L, Bernard D, Guitton J. Quantification of β-aminopropionitrile, an inhibitor of lysyl oxidase activity, in plasma and tumor of mice by liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2014 Jul;28(7):1017-23. Abstract ICI
Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Boumendjel A, Gèze A, Freyer G, Tod M. Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model. Fundam Clin Pharmacol. 2014 Apr;28(2):161-9. Abstract ICI
Carlier J, Guitton J, Bévalot F, Fanton L, Gaillard Y. The principal toxic glycosidic steroids in Cerbera manghas L. seeds: Identification of cerberin, neriifolin, tanghinin and deacetyltanghinin by UHPLC-HRMS/MS, quantification by UHPLC-PDA-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 1;962:1-8. Abstract ICI
Carlier J, Romeuf L, Guitton J, Priez-Barallon C, Bévalot F, Fanton L, Gaillard Y. A validated method for quantifying atractyloside and carboxyatractyloside in blood by HPLC-HRMS/MS, a non-fatal case of intoxication with Atractylis gummifera L. J Anal Toxicol. 2014 Nov-Dec;38(9):619-27. Abstract ICI
Carlier J, Guitton J, Romeuf L, Bévalot F, Boyer B, Fanton L, Gaillard Y. Screening approach by ultra-high performance liquid chromatography-tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to forensic toxicology. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Nov 1;975C: 65-76. Abstract ICI
Carlier J, Guitton J, Moreau C, Boyer B, Bévalot F, Fanton L, Habyarimana J, Gault G, Gaillard Y. A validated method for quantifying hypoglycin A in whole blood by UHPLC-HRMS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Dec 9;978-979C:70-77. Abstract ICI
Boissan M, Montagnac G, Shen Q, Griparic L, Guitton J, Romao M, Sauvonnet N, Lagache T, Lascu I, Raposo G, Desbourdes C, Schlattner U, Lacombe ML, Polo S, van der Bliek AM, Roux A, Chavrier P. Membrane trafficking. Nucleoside diphosphate kinases fuel dynamin superfamily proteins with GTP for membrane remodeling. Science. 2014 Jun 27;344(6191):1510-5. Abstract ICI
Valour F, Karsenty J, Bouaziz A, Ader F, Tod M, Lustig S, Laurent F, Ecochard R, Chidiac C, Ferry T; Lyon BJI Study Group. Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Feb;58(2):746-55. Abstract ICI
Martinez L, Arnaud O, Henin E, Tao H, Chaptal V, Doshi R, Andrieu T, Dussurgey S, Tod M, Di Pietro A, Zhang Q, Chang G, Falson P. Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoprotein. FEBS J. 2014 Feb;281(3):673-82. Abstract ICI
Hénin E, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Freyer G, Vidal M, Goldwasser F, Tod M. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS). Cancer Chemother Pharmacol. 2014 Feb;73(2):287-97. Abstract ICI
Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, Vial T, Trillet-Lenoir V, Freyer G, Berard F, Rioufol C. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014 Jan 13;15(1):1. doi: 10.1186/2050-6511-15-1. Abstract ICI
Payen L, Honorat M, Guitton J, Gauthier C, Bouard C, Lecerf-Schmidt F, Peres B, Terreux R, Gervot H, Rioufol C, Boumendjel A, Puisieux A, Di Pietro A. MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget. 2014 Dec 15;5(23):11957-70. Abstract ICI
Rioufol C, Ranchon F, Schwiertz V, Vantard N, Joue E, Gourc C, Gauthier N, Guedat MG, Salles G, Souquet PJ, Favier B, Gilles L, Freyer G, You B, Trillet-Lenoir V, Guitton J. Administration of anticancer drugs: exposure in hospital nurses. Clin Ther. 2014 Mar 1;36(3):401-7. Abstract ICI
Matanza D, Hallouard F, Rioufol C, Fessi H, Fraysse M. Improving radiopharmaceutical supply chain safety by implementing bar code technology. Nucl Med Commun. 2014 Nov;35(11):1179-87. Abstract ICI
Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F. ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs. 2014 May-Jun;6(3):794-9. Abstract ICI
Wilbaux M, Henin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B. Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecol Oncol 2014,133(3):460-466. Abstract ICI
Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B. Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. Br J Cancer. 2014 Mar 18;110(6):1517-24. Abstract ICI
Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O, You B. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol. 2014 Jan;25(1):41-56. Abstract ICI
Le Saux O, You B, Freyer G. Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series. Clin Breast Cancer. 2014 Jun;14(3):e89-94. Abstract ICI
B. You, O. Colomban, M. Wilbaux, E. Hénin, M. Tod, G. Freyer, T. Hajri, J. Massardier, F. Golfier. Prédiction de la résistance à la chimiothérapie des tumeurs trophoblastiques gestationnelles (TTG) de bas risque par l’analyse de la cinétique des hCG. Oncologie June 2014, Volume 16, Issue 6, pp 300-30. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Mélanie Wilbaux, Michel Tod, Johann De Bono, David Lorente, Joaquin Mateo, Gilles Freyer, Benoit You, Emilie Hénin. A dynamic K-PD joint model for the kinetics of CTC (Circulating Tumor Cell) count and PSA concentration during treatment in metastatic castration-resistant prostate cancer. 23rd PAGE Meeting – Lewis Sheiner Student Session, June 2014, Alicante, Spain. Abstract published in Abstracts of the Annual Meeting of the Population Approach Group in Europe: PAGE 23 (2014) Abstr 3029
Pierrillas P, Hénin E, Bouzom F, Tod M. Preclinical evaluation of the dose – concentration – marker – tumor growth relationship of a new pro-apoptotic compound using population PK-PD modeling. PAGE 23 (2014) Abstr 3165
Abstracts ASCO (American Society of Clinical Oncology)
Peter Andrew Kaufman, Gilles Freyer, Margaret Kemeny, Anthony Goncalves, Guy Heinrich Maria Jerusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanayakkara, Benjamin Wu, Cheryl Ann Pickett-Gies, Hans Wildiers. A phase 1b study of trebananib plus paclitaxel (P) and trastuzumab (T) in patients (pts) with HER2+ locally recurrent or metastatic breast cancer (MBC). Proc ASCO 2014. Abs 502
Abstracts Consortium Simcyp2014
Pierrillas P, Hénin E, Ball K, Bouzom F, Tod M. Translational approaches to extrapolate tumor growth inhibition effects of a new compound, from mouse to human using Simcyp. Consortium Simcyp2014, UK.
Other Abstracts
Pierrillas P, Hénin E, Bouzom F, Tod M. From mouse to human: translational approaches at the crossroads of semi-mechanistic population PKPD modelling, in vitro-in vivo extrapolation (IVIVE) and Physiologically-based PK-PD. Oral communication. GMP 2014, France.
Pierrillas P, Hénin E, Bouzom F, Tod M. Understanding the dose-response relationship of a pro-apoptotic compound in mice through PK-PD modeling. Oral communication. P2T 2014, France.
Articles
Péron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol. 2013 Nov 1;31(31):3957-63. Abstract ICI
Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J. 2013 Oct;15(4):1242-52. Abstract ICI
Martinez L, Arnaud O, Henin E, Tao H, Chaptal V, Doshi R, Andrieu T, Dussurgey S, Tod M, Di Pietro A, Zhang Q, Chang G, Falson P. Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoprotein. FEBS J. 2014 Feb;281(3):673-82. Abstract ICI
Valour F, Karsenty J, Bouaziz A, Ader F, Tod M, Lustig S, Laurent F, Ecochard R, Chidiac C, Ferry T; Lyon BJI Study Group. Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Feb;58(2):746-55. Abstract ICI
Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, Jestin-Le Tallec V, Kirsher S, Leyronnas C, Ligeza-Poisson C, Ramdane S, Salavt J, Van-Hult S, Vannetzel JM, Freyer G, Tod M, Falandry C. Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.J Geriatr Oncol. 2013 Jan;4(1):48-57. Abstract ICI
Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Target Oncol. 2013 Dec;8(4):243-51. Abstract ICI
Hénin E, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Freyer G, Vidal M, Goldwasser F, Tod M. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS). Cancer Chemother Pharmacol. 2014 Feb;73(2):287-97. Abstract ICI
Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Valdameri G, Geze A, Boumendjel A, Freyer G, Tod M. A template model for studying anticancer drug efflux transporter inhibitors in vitro. Fundam Clin Pharmacol. 2013 Oct;27(5):544-56. Abstract ICI
Aurélien Bde H, Sylvie B, Alain D, Jérôme G, Yves P. Ecotoxicological risk assessment linked to the discharge by hospitals of bio-accumulative pharmaceuticals into aquatic media: The case of mitotane. Chemosphere. 2013 Nov;93(10):2365-72. Abstract ICI
Jacolot A, Judel C, Louchahi K, Tod M, Marchand S, Petitjean O, Mimoz O. How to solve the problem of spontaneous bacterial clearance when testing new antibiotic treatment: results on experimental pneumonia due to a derepressed cephalosporinase-producing Enterobacter cloacae. Fundam Clin Pharmacol. 2013 Jun;27(3):239-43. Abstract ICI
Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, Nony P; Genophar Working Group. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet. 2013 Mar;52(3):199-209.Abstract ICI
Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M; Genophar II Working Group.In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates.AAPS J. 2013 Apr;15(2):415-26. Abstract ICI
Hamizi S, Freyer G, Bakrin N, Henin E, Mohtaram A, Le Saux O, Falandry C. Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.Onco Targets Ther. 2013;6:89-94. Abstract ICI
Freyer G, Jovenin N, Yazbek G, Villanueva C, Hussain A, Berthune A, Rotarski M, Simon H, Boulanger V, Hummelsberger M, Falandry C. Granocyte-colony Stimulating Factor (G-CSF) Has Significant Efficacy as Secondary Prophylaxis of Chemotherapy-induced Neutropenia in Patients with Solid Tumors: Results of a Prospective Study. Anticancer Res. 2013 Jan;33(1):301-7. Abstract ICI
André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, Blay JY, Milano G. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics. 2013 Jun;14(8):931-9. Abstract ICI
Goutelle S, Baudry T, Gagnieu MC, Boibieux A, Livrozet JM, Peyramond D, Chidiac C, Tod M, Ferry T; Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients. on behalf of the Lyon HIV Cohort Study Group. Antimicrob Agents Chemother. 2013 Jan;57(1):517-523. Abstract ICI
Benjamin L, Buthion V, Iskedjian M, Farah B, Rioufol C, Vidal-Trécan G. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. J Med Econ. 2013;16(1):96-107. Abstract ICI
Benoit You, Richard Harvey, Emilie Henin, Hugh Mitchell, François Golfier, Philip M Savage, Michel Tod, Melanie Wilbaux, Gilles Freyer, Michael J Seckl. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer, 2013 May 14;108(9):1810-6. Abstract ICI
Julien Péron, Benoit You, Hui K Gan, Denis Maillet, Eric X Chen, Gregory Pond. Influence of statistician involvement on reporting of randomized clinical trials in medical oncology. Anticancer Drugs. 2013 Mar;24(3):306-9. Abstract ICI
Julien Péron and Benoit You. Correspondance. J Natl Cancer Inst 2013; 105(3): 244-245.
F Lignet, S Benzekry, Shebby Wilson, F Billy, O Saut, Michel Tod, Benoit You, A Adda Berkane, S Kassour, Ming X Wei, Emmanuel Grenier, Benjamin Ribba. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. J Theor Biol. 2013 Mar 7;320:86-99. Abstract ICI
Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, Nony P; Genophar Working Group. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.Clin Pharmacokinet. 2013 Mar;52(3):199-209. Abstract ICI
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. 2013 Aug;130(2):289-94. Abstract ICI
Rhondali W, Tremellat F, Ledoux M, Ciais JF, Bruera E, Filbet M. Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. J Palliat Med. 2013 Nov;16(11):1382-7. Abstract ICI
Ledoux M, Rhondali W, Monnin L, Thollet C, Gabon P, Filbet M. Advanced directives: nurses' and physicians' representations in 2012. Bull Cancer. 2013 Oct 1;100(10):941-945. Abstract ICI
Rhondali W, Ledoux M, Sahraoui F, Marotta J, Sanchez V, Filbet M. [Management of psychiatric impatients with advanced cancer: a pilot study]. Bull Cancer. 2013 Sep;100(9):819-27. Abstract ICI
Rhondali W, Lasserre E, Filbet M. Art therapy among palliative care impatients with advanced cancer. Palliat Med. 2013 Jun;27(6):571-2. Abstract ICI
Rhondali W, Yennurajalingam S, Chisholm G, Ferrer J, Kim SH, Kang JH, Filbet M, Bruera E. Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients. Support Care Cancer. 2013 Sep;21(9):2427-35. Abstract ICI
Dev R, Coulson L, Del Fabbro E, Palla SL, Yennurajalingam S, Rhondali W, Bruera E. A prospective study of family conferences: effects of patient presence on emotional expression and end-of-life discussions.J Pain Symptom Manage. 2013 Oct;46(4):536-45. Abstract ICI
Rhondali W, Burt S, Wittenberg-Lyles E, Bruera E, Dalal S. Medical oncologists' perception of palliative care programs and the impact of name change to supportive care on communication with patients during the referral process. A qualitative study.
Palliat Support Care. 2013 Oct;11(5):397-404. Abstract ICI
Rhondali W, Chisholm GB, Daneshmand M, Allo J, Kang DH, Filbet M, Hui D, Fingeret MC, Bruera E. Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report.
J Pain Symptom Manage. 2013 Jun;45(6):1039-49. Abstract ICI
Rhondali W, Perez-Cruz P, Hui D, Chisholm GB, Dalal S, Baile W, Chittenden E, Bruera E. Patient-physician communication about code status preferences: A randomized controlled trial. Cancer. 2013 Jun 1;119(11):2067-73. Abstract ICI
Nguyen LM, Rhondali W, De la Cruz M, Hui D, Palmer L, Kang DH, Parsons HA, Bruera E. Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer.J Pain Symptom Manage. 2013 Mar;45(3):506-16. Abstract ICI
Rhondali W, Nguyen L, Palmer L, Kang DH, Hui D, Bruera E. Self-reported constipation in patients with advanced cancer: a preliminary report. J Pain Symptom Manage. 2013 Jan;45(1):23-32. Abstract ICI
Bévalot F, Gustin MP, Cartiser N, Gaillard Y, Le Meur C, Fanton L, Guitton J, Malicier D. Using bone marrow matrix to analyze meprobamate for forensic toxicological purposes. Int J Legal Med. 2013 Sep;127(5):915-21. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Mélanie Wilbaux, Emilie Henin, Olivier Colomban, Amit Oza, Eric Pujade-Lauraine, Gilles Freyer, Benoit You1, Michel Tod. A drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancer patients. PAGE 22 (2013) Abstr 2716
HENIN Emilie,BLANCHET Benoit, TOD Michel. Optimization of sorafenib dosing regimen using the concept of utility. PAGE 22 (2013) Abstr
2830
Abstracts ASCO (American Society of Clinical Oncology)
Benefit in Progression-Free Survival to expect based on CA-125 reduction at week 6 in recurrent ovarian cancer patients Mélanie Wilbaux, Emilie Henin, Olivier Colomban, Amit Oza, Eric Pujade-Lauraine, Gilles Freyer, Michel Tod, Benoit You
Articles
Preuss J, Gazon M, Mabrut JY, Duperret S, Mezoughi S, Tod M, Ducerf C, Charpiat B. Tacrolimus trough levels before, during and after jejunostomy in a liver transplant patient: a case report. Clin Res Hepatol Gastroenterol. 2012 Dec;36(6):e126-30. Abstract ICI
You B, Gan HK, Pond G, Chen EX. Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol. 2012 Jan 10;30(2):210-6. Abstract ICI
Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Target Oncol. 2012 Dec 13. Abstract ICI
Paule I, Girard P, Freyer G, Tod M. Pharmacodynamic models for discrete data Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Abstract ICI
Bauler S, Janoly-Dumenil A, Sancho PO, Fromager F, Gouraud A, Rioufol C, Jacquin-Courtois S, Luaute J, Rode G. Effect of Carbamazepine on Fluindione's Anticoagulant Activity: a Case Report. Therapie. 2012 Sep;67(5):488-489. Epub 2012 Dec 18.
Freyer G, Isambert N, You B, Zanetta S, Falandry C, Favier L, Trillet-Lenoir V, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Fumoleau P. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. Br J Cancer. 2012 Aug 7;107(4):598-603.Abstract ICI
Janoly-Dumenil A, Rouvet I, Bleyzac N, Morfin F, Zabot MT, Tod M. A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection. Antimicrob Agents Chemother. 2012 Jul;56(7):3732-8. doi: 10.1128/AAC.06423-11. Epub 2012 Apr 23. Abstract ICI
Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer. 2012 May 22;106(11):1728-34. Abstract ICI
Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients. Ann Surg Oncol. 2012 Jul 24.Abstract ICI
Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B. Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study.B.PLoS One. 2012;7(8):e42875. Abstract ICI
Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F. A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy.Clin Cancer Res. 2012 Aug 1. Abstract ICI
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E.J. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. Clin Oncol. 2012 Aug 1;30(22):2718-24. Abstract ICI
Bartoli M, Berny C, Danel V, Delahaye A, Desch G, Guitton J, Lacarelle B, Lapostolle F, Mathieu D, Mégarbane B, Nisse P, Szymanowicz A, Capolaghi B. Recommendations for the prescription, implementation and interpretation of medical examinations in biology in the context of severe poisoning. Ann Biol Clin (Paris). 2012 Aug 1;70(4):431-450. Abstract ICI
Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.J Natl Cancer Inst. 2012 Jul 3;104(13):982-9. Abstract ICI
Passot G, Vaudoyer D, Cotte E, You B, Isaac S, Noël Gilly F, Mohamed F, Glehen O. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012 Jul;256(1):125-9. Abstract ICI
You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V, Siu LL. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.Am J Clin Oncol. 2012 Jun;35(3):255-60. Abstract ICI
Sostelly A, Payen L, Guitton J, Pietro AD, Falson P, Honorat M, Valdameri G, Geze A, Boumendjel A, Freyer G, Tod M. A template model for studying anticancer drug efflux transporter inhibitors in vitro.Fundam Clin Pharmacol. 2012 Jun 10. Abstract ICI
Moussata D, Bessayah A, Chauvenet M, Stroeymeyt K, Boschetti G, Cotte E, Glehen O, Issac S, Mornex F, Freyer G, Lombard-Bohas C, Saurin JC, Flourie B. A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Gastrointest Cancer Res. 2012 May;5(3):106-8. Abstract ICI
Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N, Franchon E, Dussart C, Henin E, Colomban O, Girard P, Freyer G, Rioufol C. Predictors of prescription errors involving anticancer chemotherapy agents. Eur J Cancer. 2012 May;48(8):1192-9. Abstract ICI
Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G. Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol. 2012 Apr;73(4):597-605. Abstract ICI
Rhondali W, Perceau E, Saltel P, Trillet-Lenoir V, Blay JY, Fournel-Federico C, Coulon JP, Tredan O, Terra JL, Matillon Y, Bruera E, Filbet M. Depression assessment by oncologists and palliative care physicians. Palliat Support Care. 2012 May 15:1-9.
Abstract ICI
Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst. 2012 Apr 18;104(8):590-8.
Abstract ICI
Kurtz JE, Freyer G, Joly F, Gladieff L, Kaminski MC, Fabbro M, Floquet A, Hardy-Bessard AC, Raban N, Ray-Coquard I, Pujade-Lauraine E, GINECO Group, France. Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial. Anticancer Res. 2012 Mar;32(3):1045-9.
Abstract ICI
Isambert N, Freyer G, Zanetta S, You B, Fumoleau P, Falandry C, Favier L, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Trillet-Lenoir V. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 15;18(6):1743-50.
Abstract ICI
Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. 2012 Mar;11(1):38-44.
Abstract ICI
Valdameri G, Pereira Rangel L, Spatafora C, Guitton J, Gauthier C, Arnaud O, Ferreira-Pereira A, Falson P, Winnischofer SM, Rocha ME, Tringali C, Pietro AD. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem Biol. 2012 Feb 17;7(2):322-30.
Abstract ICI
Rhondali W, Perceau E, Berthiller J, Saltel P, Trillet-Lenoir V, Tredan O, Coulon JP, Bruera E, Filbet M. Frequency of depression among oncology outpatients and association with other symptoms. Support Care Cancer. 2012 Feb 17.
Abstract ICI
Paule I, Tod M, Hénin E, You B, Freyer G, Girard. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. Cancer Chemother Pharmacol. 2012 Feb;69(2):447-55.
Abstract ICI
Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SM, Rocha ME, Boumendjel A, Di Pietro A.J. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. Med Chem. 2012 Jan 26;55(2):966-70.
Abstract ICI
You B, Gan HK, Pond G, Chen EX. Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol. 2012 Jan 10;30(2):210-6.
Abstract ICI
You B, Pond G., Siu L, Nagai G, Cheiken R, Chen E. Heterogeneity among lists of cautioned or prohibited drugs in protocols of early phase oncology trials. Ann Oncol (2012) 23(6): 1633-1639.
Abstract ICI
Verstuyft C, Delavenne X, Rousseau A, Robert A, Tod M, Diquet B, Lebot M, Jaillon P, Becquemont L. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet. 2012 Jan 1;51(1):41-53.
Abstract ICI
Roy B, Vo Duy S, Puy J-Y, Martin C, Guitton J, Dumontet C, Périgaud C, Lefebvre-Tournier I. Synthesis and Evaluation of a Molecularly Imprinted Polymer for Selective Solid-Phase Extraction of Irinotecan from Human Serum Samples. J Funct Biomater 2012, 3(1), 131-142.
Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Wilbaux M,You B, Hénin E, Colomban O, Freyer G, Tod M. Population K-PD joint modeling of tumor size and CA 125 kinetics after chemotherapy in relapsed ovarian cancer (ROC) patients. PAGE 21 (2012) Abstr 2587
Sostelly A, Nyberg J, karlsson M.O, Hooker A.C. Dose and dose schedule optimization of anticancer drugs. PAGE 21 (2012) Abstr 2373
Quelin A, Tod M, Henin E. How Anti-cancer Targeted Therapies Used in Combination Interact: Analysis with a Semi-Mechanistic Model of Minimal Signaling Networks. PAGE 21 (2012) Abstr 2361
Hénin E, Blanchet B, Boudou-Rouquette P, Freyer G, Goldwasser F, Tod M.A latent-variable model for Sorafenib-induced HFS in cancer non-selected patients to predict toxicity kinetics. PAGE 21 (2012) Abstr 2494
Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Tod M. Determination of the most influential sources of variability of tacrolimus trough blood levels in adult liver transplant patients: a bottom-up approach. PAGE 21 (2012) Abstr 2597
Abstracts ASCO (American Society of Clinical Oncology)
Barthelemy P., Bassot K, Joly F, Ray Coquard I, Freyer G, Dufour P R, Campos F, Kurtz J. Adjuvant treatment of early-stage HER2+ elderly breast cancer patients: A retrospective, multicenter French study. (Abstract 636)
G. Freyer, B.E. Weber, D. Lebrun-Jezekova, F. Tinquaut, O. Tredan, E. Sevin, L. Stefani, E. Pujade-Lauraine, C. Falandry. Development of a geriatric vulnerability score (GVS) in elderly advanced ovarian cancer (AOC) patients (pts) treated in first line : A prospective GINECO trial. (Abstract 9079)
M. Filbet, W. Rhondali, G. Freyer, V. Adam, M. Dezerile, G. Abgrall-Barbry, S. Gobet-Bourcelot, J. Machavoine, M. Chomat-Neyraud, N. Gane, P. Saltel, C. Falandry. Correlations between depression according DSM-IV-TR (DSM) criteria, three validated scales, oncologist assessment, and clinical psychiatric interview in elderly advanced ovarian cancer (AOC) patients (pts) : A GINECO study. (abstract 9080)
Phase Ib study of open-label AMG 386 plus paclitaxel (P) and trastuzumab (T) or capecitabine (C) and lapatinib (L) in patients (pts) with HER2 + locally recurrent or metastatic breast cancer (MBC). (Abstract 529) H. Wildiers, A. Goncalves, M. Kemeny, R.E. Swart, G. Freyer, N. Nanayakkara, B. Wu, C.A. Pickett-Gies, P.A. Kaufman.
C. Falandry, B. Horard, J. Alexandre, G. Deplanque, O. Cojocarasu, J. Salvat, E. Legouffe, J. Cretin, J. Meunier, R. Maraval-Gaget, D. Micheau-Bonnier, E. Gilson, G. Freyer. Correlation of short telomeres (ST) with vulnerability,toxicity, and early death in elderly AOC patients receiving carboplatin : a multicenter GINECO trial. (abstract 9011)
O. Bally, G. Freyer, A. Salles, A. Michallet, O. Casasnovas, H. Tilly, V. Ribrag, C. Sebban, C. Falandry, B. You. Prognostic value of etoposide area under the curve (AUC) in lymphoma patients treated with BEAM regimen and ASCT : Multicenter study of Groupe d’Etudes des lymphomes de l’adulte (GELA).(Abstract 8068)
Articles
Guiu S, Liegard M, Favier l, Van Praagh i, Larguillier r, Weber b, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir v, Arnould L, Coudert B. Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy Ann Oncol. 2011;22(2):321. Abstract ICI
Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S, Broussais F, You B, Tartas S, Souquet PJ, Dussart C, Falandry C, Henin E, Freyer G, Rioufol C. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 2011 Nov 8;11:478. Abstract ICI
Falandry C, Bonnefoy M, Freyer G. Revisiting the frontiers of pharmacogenomics of colon cancer. Falandry C, Bonnefoy M, Freyer G. Pharmacogenomics. 2011 Sep;12(9):1243-8. Abstract ICI
Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M. [Node negative breast cancer. Beyond international consensus: a pragmatic approach]. Bull Cancer. 2011 Jul;98(7):807-25. Abstract ICI
Spano JP, Falandry C, Chaibi P, Freyer G. Current targeted therapies in breast cancer: clinical applications in the elderly woman. Oncologist. 2011;16(8):1144-53. Abstract ICI
Freyer G, Campone M, Peron J, Facchini T, Terret C, Berdah JF, Jacquin JP, Coeffic D, Hilaire Pde S, Falandry C. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol Hematol. 2011 Dec;80(3):466-73. Abstract ICI
Freyer G, Tinker AV; Clinical trials and treatment of the elderly diagnosed with ovarian cancer. Freyer G, Tinker AV. Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):776-81. Abstract ICI
Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; First-line therapy in ovarian cancer trials. Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):756-62. Abstract ICI
Freyer G, Duret A, Milano G, Chatelut E, Rebischung C, Delord JP, Merrouche Y, Lledo G, Etienne MC, Falandry C. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer Res. 2011 Jan;31(1):359-66. Abstract ICI
Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. 2011 Feb;47(3):479-90. Epub 2010 Nov 10. PMID: 21074409 [PubMed - indexed for MEDLINE] Abstract ICI
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model. Pharm Res. 2011 Mar;28(3):531-9. Epub 2010 Oct 21. Abstract ICI
Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, Mir O, Abbas H, Harcouet L, Coriat R, Dauphin A, Goldwasser F, Tod M.Saturable absorption of sorafenib in patients with solid tumors: a population model.
Invest New Drugs. 2011 Oct 18. Abstract ICI
Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, Goujard C, Taburet AM, Lortholary O, Leroy V, Bélec L. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.; ANRS EP24 GYNODYN Study Group. Antivir Ther. 2011;16(6):843-52. Abstract ICI
Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011 Aug;50(8):519-30. Abstract ICI
Tod M, Mir O, Bancelin N, Coriat R, Thomas-Schoemann A, Taieb F, Boudou-Rouquette P, Ropert S, Michels J, Abbas H, Durand JP, Dauphin A, Vidal M, Goldwasser F, Blanchet B.Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res. 2011 Dec;28(12):3199-207. Abstract ICI
Paule I, Tod M, Hénin E, You B, Freyer G, Girard P. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. Cancer Chemother Pharmacol. 2011 Aug 2. Abstract ICI
Paule I, Sassi H, Habibi A, Pham KP, Bachir D, Galactéros F, Girard P, Hulin A, Tod M. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis. 2011 May 28;6:30. Abstract ICI
Paule I, Girard P, Tod M. Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data. Comput Methods Programs Biomed. 2011 Dec;104(3):505-13. Abstract ICI
Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, Steghens A, Mohamed F, Glehen O. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011 Sep;18(9):2599-603. Abstract ICI
Puech R, Gagnieu MC, Planus C, Charpiat B, Boibieux A, Ferry T, Tod M. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir. Br J Clin Pharmacol. 2011 Apr;71(4):621-3. Abstract ICI
Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G.A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. 2011 Feb;47(3):479-90. Abstract ICI
Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):25-40. Abstract ICI
Vial Y,. Tod M, Hornecker M, Conti F, Dauphin A,. Calmus Y, Blanchet B. In vitro influence of bilirubin and fatty acids on binding of mycophenolic acid to human serum albumin. J Pharm Biomed Anal, 2011, 54, 607-609. Abstract ICI
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model. Pharm Res. 2011 Mar;28(3):531-9. Abstract ICI
Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. Abstract ICI
Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S, Broussais F, You B, Tartas S, Souquet PJ, Dussart C, Falandry C, Henin E, Freyer G, Rioufol C. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 2011 Nov 8;11:478. Abstract ICI
You B, Chen EX. Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. J Clin Pharmacol. 2011 Mar 22. Abstract ICI
You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V, Siu LL. A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. Am J Clin Oncol. 2011 Feb 22. Abstract ICI
Basanta D, Ribba B, Watkin E, You B, Deutsch A. Math Computational analysis of the influence of the microenvironment on carcinogenesis. Math Biosci. 2011 Jan;229(1):22-9. Epub 2010 Oct 31. Abstract ICI
You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
Invest New Drugs. 2011 Oct;29(5):996-1003. Epub 2010 May 8. Abstract ICI
Nambaru PK, Hübner T, Köck K, Mews S, Grube M, Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach C, Rosskopf D, Kowalczyk DW, Kroemer HK, Weiss FU, Mayerle J, Lerch MM, Ritter CA. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos, 2011;39(1):132-139. Abstract ICI
Cotte E, Colomban O, Guitton J, Tranchand B, Bakrin N, Gilly FN, Glehen O, Tod M. Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Hyperthermic Intraperitoneal Chemotherapy Using a Closed Abdominal Procedure. J Clin Pharmacol, 2011;51(1):9-18. Abstract ICI
Honorat M, Guitton J, Dumontet C, Payen L. Expression level and hormonal regulation of ABC transporters in breast cancer. Current Cancer Therapy Review, 2011; 7(2): 119-154. Book.
Arnaud O, Boumendjel A, Gèze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P, Dumontet C, Di Pietro A, Payen L. The acridone derivative MBLI-87 reverses breast cancer resistance protein-mediated resistance to irinotecan in xenografts. Eur J Cancer 2011;47(4):640-8. Abstract ICI
Bougarel L, Guitton J, Zimmer L, Vaugeois JM, El Yacoubi M. Behaviour of a genetic mouse model of depression in the learned helplessness paradigm. Psychopharmacology 2011; 215(3):595-605. Abstract ICI
Gaillard Y, Carlier J, Berscht M, Mazoyer C, Bevalot F, Guitton J, Fanton L. Fatal intoxication due to ackee (Blighia sapida) in Suriname and French Guyana. GC-MS detection and quantification of hypoglycin-A. Forensic Sci Int 2011 20;206(1-3):e103-7. Abstract ICI
Cartiser N, Bévalot F, Fanton L, Gaillard Y, Guitton J. State-of-the-art of bone marrow analysis in forensic toxicology: a review. Int J Legal Med 2011;125(2):181-98. Abstract ICI
Cartiser N, Bévalot F, Chatenay C, Le Meur C, Gaillard Y, Guitton J, Fanton L. Postmortem measurement of caffeine in bone marrow: Influence of sample location and correlation with blood concentration. Forensic Sci Int 2011; 210(1-3):149-153. Abstract ICI
Cartiser N, Bévalot F, Le Meur C, Gaillard Y, Malicier D, Hubert N, Guitton J. Gas chromatography-tandem mass spectrometry assay for the quantification of four benzodiazepines and citalopram in eleven postmortem rabbit fluids and tissues, with application to animal and human samples. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879(27):2909-2918. Abstract ICI
Guffon N, Bin-Dorel S, Decullier E, Paillet C, Guitton J, Fouilhoux A. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J Pediatr 2011 Nov;159(5):838-844. Abstract ICI
Tod M, Goutelle S, Gagnieu MC, and the Genophar II Working Group*. Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. Clin Pharmacol Ther 2011, Oct;90(4):582-7. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Bonnefois G, Payen L, Guitton J, Freyer G, Rouvet I, Tod M. Does the active transport of albumin play a role on sorafenib distribution in human pulmonary artery endothelial cells? PAGE 20 (2011) Abstr 2094
Gérard C, Verstuyft C, Stocco J, Hulin A, Blanchet B, Tod M. Factors influencing pharmacokinetics of tacrolimus during the early liver posttransplantation period: a population analysis. PAGE 20 (2011) Abstr 2065
Sostelly A, Payen L, Guitton J, Boumendjel A, Di Pietro A, Falson P, Freyer G, Tod M. Characterization of the interaction between irinotecan, SN-38 and MBLI-98,a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model. PAGE 20 (2011) Abstr 2091
Tod M, Goutelle S, Gagnieu M-C, and the Genophar II Working Group. A meta-analysis regression model for quantitative prediction of the impact of polymorphism on drug exposure. PAGE 20 (2011) Abstr 1964
Wilbaux M, You B, Colomban O, Oza A-M, Freyer G, Henin H, Tod M. Population K-PD modeling of CA 125 and tumor size kinetics in relapsed ovarian cancer patients. PAGE 20 (2011) Abstr 2200
Abstracts ASCO (American Society of Clinical Oncology)
You B, Colomban O, Heywood M, Oza A. M. Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial (a GCIG study). J Clin Oncol ASCO Annual Meeting Proceedings;2011 29, suppl; abstr 5065
Articles
Masciullo M, Santoro M, Modoni A, Ricci E, Guitton J, Tonali P, Silvestri G. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. Inherit Metab Dis. 2010 Sep 4 . Abstract ICI
Cohen S, Jordheim LP, Megherbi M, Dumontet C, Guitton J. Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: a review. Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jul 15;878(22):1912-28 . Abstract ICI
Benichou AS, B. Blanchet, F. Conti, M. Hornecker, D. Bernard, F. Taieb, O. Scatton, H. Abbas, L. Harcouet, A. Dauphin, Y. Calmus, M. Tod. Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early post-transplantation period. J Clin Pharmacol. 2010;50(10):1202-10 . Abstract ICI
Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. 2011 Feb;47(3):479-90. Epub 2010 Nov 10. . Abstract ICI
Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. JJ Pharmacokinet Pharmacodyn. 2011 Feb;38(1):25-40. Epub 2010 Nov 4 . Abstact ICI
You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2010 In Press. Abstract ICI
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model. Pharm Res. 2010 Sep 2 In Press. Abstract ICI
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model. Pharm Res. 2010 In Press. Abstract ICI
Cotte E, Colomban O, Guitton J, Tranchand B, Bakrin N, Gilly FN, Glehen O, Tod M. Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Hyperthermic Intraperitoneal Chemotherapy Using a Closed Abdominal Procedure. J Clin Pharmacol. 2010 Feb 19 In Press. Abstract ICI
Freyer G, Hernández-Sánchez J, Vukasinovic N. Effect of family relatedness on characteristics of estimated IBD probabilities in relation to precision of QTL estimates. BMC Genet 2010 Sep 26;11:85. Abstract ICI
Falandry C, Campone M, Cartron G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010 Sep;46(13):2389-2398. Abstract ICI
You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. Urology. 2010 Aug;76(2):423-429. Abstract ICI
You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. 2010 Aug;21(8):1643-1650. Abstract ICI
Steimer Jl, Dahl Sg, De Alwis Dp, Gundert-Remy U, Karlsson Mo, Martinkova J, Aarons L, Ahr Hj, Clairambault J, Freyer G, Friberg Le, Kern Se, Kopp-Schneider A, Ludwig Wd, De Nicolao G, Rocchetti M, Troconiz I. Modelling the genesis and treatment of cancer: the potential role of physiologically base pharmacodynamics. Eur J Cancer 2010 Jan; 46(1):21-32. Abstract ICI
Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol. 2010 Mar;65(4):755-763. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Influence of cyclosporin dosing schedule on receptor occupancy in bone marrow transplantation: analysis with a PBPK-PD model. PAGE 19 (2010) Abstr 1924
Colomban O, Naudet B, Maucort-Boulch, Roy, Girard P. Toxicogenomic dose-response models for DNA chips data from rats treated by flutamide. PAGE 19 (2010) Abstr 1854
Paule I, Girard P, Tod M. Estimation of Individual Parameters of a Mixed–Effects Dose-Toxicity Model for Ordinal Data. PAGE 19 (2010) Abstr 1785
Ribba B,, Watkin E, Tod M, Girard P, Grenier E, You B, Wei M, Giraudo E, Freyer G. Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice. PAGE 19 (2010) Abstr 1801
Sostelly A, Payen L, Ribba B, Di Pietro A, Falson P, Girard P, Tod M. Modelling the interaction between Irinotecan and efflux transporters inhibitors: A KPD tumour growth inhibition model including interaction components. PAGE 19 (2010) Abstr 1706
Abstracts ASCO (American Society of Clinical Oncology)
Boudou-Rouquette P, Blanchet B, Mir O, Billemont B, Ropert S, Barete S, Coriat R, Franck N, Tod M, Goldwasser F. Proposal of a new population pharmacokinetic model of sorafenib and rationale for a three daily schedule. 2010 ASCO Annual Meeting. J Clin Oncol ASCO Annual Meeting Proceedings;2010 28:15s, suppl; abstr 3044.
Articles
D Ternant, E Hénin, G Cartron, M Tod, G Paintaud, P Girard. Development of a drug by disease simulation model for rituximab in follicular non-Hodgkin lymphoma. Br J Clin Pharmacol. 2009 oct;68(4):561-573. Abstract ICI
Hénin E, Tod M, Trillet-Lenoir V, Rioufol C, Tranchand B, Girard P. Pharmacokinetically Based Estimation of Patient Compliance with Oral Anticancer Chemotherapies: In Silico Evaluation. Clin Pharmacokinet 2009 Jun 6;48(6):359-369. Abstract ICI
Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics. J Clin Oncol 2009 Sep 1;27(25):4103-4108. Abstract ICI
Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009 Apr;20(4):615-20. Abstract ICI
Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 2009 Aug;116(3):501-508. Abstract ICI
You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate. 2009 Sep 1;69(12):1325-1333. Abstract ICI
Hénin E, You B, Vancutsem E, Hoff P, Cassidy J, Twelves C, Zuideveld K, Sirzen F, Dartois C, Freyer G, Tod M, Girard P. A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clin Pharmacol Ther 2009;85:418-425. Abstract ICI
Ribba B, You B, Tod M, Girard P, Tranchand B, Trillet-Lenoir V, Freyer G. Chemotherapy may be delivered based on an integrated view of tumour dynamics. IET Syst Biol 2009;3:180-190. Abstract ICI
Delavenne X, Laporte S, Demasles S, Mallouk N, Basset T, Tod M, Girard P, Mismetti P. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. Fundam Clin Pharmacol. 2009 Feb;23(1):127-135. Abstract ICI
Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 2009 Jun 27;404(2):134-139. Abstract ICI
Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M.V alidation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009 May 1;49(4):1109-1114. Abstract ICI
Hulin A, Blanchet B, Audard V, Barau C, Furlan V, Durrbach A, Taïeb F, Lang P, Grimbert P, Tod M. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients. Ther Drug Monit 2009 Apr;31(2):224-232. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Fronton L, You B, Pollet-Villard M, FreyerG, Tod M, Colomban O, Golfier F, Girard P Population model of Human Chorionic Gonadotropin to predict resistance in low risk gestational trophoblastic neoplasia patients. PAGE 18 (2009) Abstr 1540
Gérard C, Bleyzac N, Girard P, Tranchand B, Freyer G, Bertrand Y, Tod M. Link between cyclosporin exposure in tissues and graft versus host disease in paediatric bone marrow transplantation: analysis by a PBPK model. PAGE 18 (2009) Abstr 1608
Gérard C, Bleyzac N, Girard P, Tranchand B, Freyer G, Bertrand Y, Tod M. Influence of cyclosporin infusion duration on efficacy in paediatric bone marrow transplantation: analysis by a PBPK model. PAGE 18 (2009) Abstr 1607
Paule I, Sassi H, Habibi A, Bachir D, Galactéros F, Girard P, Hulin A, Tod M. Population Pharmacokinetics and Pharmacodynamics of Hydroxyurea in Sickle Cell Anemia Patients, In Silico Comparison of Two Dosing Regimens. PAGE 18 (2009) Abstr 1582
Ribba B, Watkin E, Tod M, Girard P, You B, Tranchand B, Grenier E, Freyer G. Estimating the kinetic parameters of vascular tumor growth models to optimize anti-angiogenesis drugs delivery. PAGE 18 (2009) Abstr 1534
Sostelly A, Hénin E, You B, Girard P, Karlsson MO. Simultaneous modelling of PSA production in Prostatic Benign Hyperplasia (PBH) and prostatic adenocarcinoma patients treated by prostate surgery. PAGE 18 (2009) Abstr 1497
Ternant D, Hénin E, Cartron G, Tod M, Paintaud G, Girard P. Model-based optimization of rituximab dosing regimen in follicular non-Hogdkin lymphoma. PAGE 18 (2009) Abstr 1519
Fontanilles M, Pilleul F, Colomban O, Tranchand B, Schott AM, Chayvialle JA, Tod M. Modelization of bevacizumab effect on tumour perfusion assessed by Dynamic Contrast Enhanced Ultrasonography. PAGE 18 (2009) Abstr 1546
Abstracts ASCO (American Society of Clinical Oncology)
Boyle H, You B, Fronton L, Ribba B, Girard P, Tranchand B, Tod M, Coquelin H, Droz JP, Flechon A. Major prognostic value of modeled AUChCG-AFP, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG. J Clin Oncol ASCO Annual Meeting Proceedings;2009 27:15s, suppl; abstr 5085.
B. Billemont, M. Hornecker, S. Ropert, B. Blanchet, J. Jais, P. Blanchard, J. Meric, J. Alexandre, M. Tod, F. Goldwasser. Correlation of sorafenib plasma concentrations and clinical toxicity: A prospective population pharmacodynamic and pharmacokinetic study. J Clin Oncol ASCO Annual Meeting Proceedings;2009 27, suppl;abstr e14585.
Articles
You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Hénin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P. Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem 2008;41(10-11):785-795. Abstract ICI
Paule I, Girard P, Tod M, Freyer G, Henin E, Tranchand B. Capecitabine dosage adaptation to prevent severe hand-and-foot syndrome: comparison of standard and model-based approaches. Fund Clin Pharmacol 2008;22(S64):14.
Tranchand B, Falandry C, You B, Girard P, Ribba B, Tod M, Freyer G. Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment. Bull Cancer 2008;95:F27. Abstract ICI
Ribba B, You B, Girard P, Tranchand B, Trillet-Lenoir V, Freyer G. Mathematic modelization of cancer: a fulcrum from fundamental research to clinical research. Bull Cancer 2008;95:S60.
Paule I, Tod M, Tranchand B, Freyer G, Henin E, Girard P. Model-based dose adaptation of capecitabine in order to prevent severe hand-and-foot syndrome: in silico comparison with the classical method. Bull Cancer 2008;95:S68
Girard P, Dartois C, Michallet M, Henin E, Vermot-Desroches C, Tranchand B, Trillet-Lenoir V, Freyer G. Development of a pharmacokinetic-pharmacodynamic model of inolimomab in GVHD patients Bull Cancer 2008;95:S74
Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A, Jouault H, Astier A, Tod M, Hulin A. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monitor 2008;30(4):412-418. Abstract ICI
Hochane M, Blanchet B, Giraudier S, Tod M, Astier A, Tulliez M, Hulin A. Practical TDM of imatinib in chronic myeloid leukaemia. Fund Clin Pharmacol 2008;2(S436)2:89
Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn 2008 Dec;35(6):619-33. Abstract ICI
Tod M, Lagneau F, Jullien V, Mimoz O. A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Pharm Res 2008;25(6):1431-1439. Abstract ICI
Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokin 2008;47(4):231-243. Abstract ICI
Dumaine V, Eyrolle L, Baixench MT, Paugam A, Larousserie F, Padoin C, Tod M, Salmon D. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine. Int J Antimicrob Agents 2008;31(4):398-399.
Cassier PA, Chabaud S, Trillet-Lenoir V, Peaud PY, Tigaud JD, Cure H, Orfeuvre H, Salles B, Martin C, Jacquin JP, Agostini C, Guastalla JP, Perol D, Bachelot,T. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 2008;109(2):343-350. Abstract ICI
Seve P, Reiman T, Isaac S, Trillet-Lenoir V, Lafanechere L, Sawyer M, Dumontet C. Protein abundance of class III beta-tubulin but not Delta 2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008;28(2B):1161-1167. Abstract ICI
Berger F, Bossard N, Chauvin F, Janier M, Marche P, Trillet-Lenoir V, Vasson MP, Zoulim F, Pauwels P. CLARA canceropole : A dynamic network oriented towards cancerology research to the patients benefit. Bull Cancer 2008,95:S3-S9
Schott AM, Raudrant D, Guastalla JP, Mathian B, Frappart L, Trillet-Lenoir V, Massardier J, Golfier F. Lyon coordination pilot plant of trophoblastic tumors. Bull Cancer 2008;95:S56
Heudel P, Romestaing P, Barbet N, Falandry C, You B, Glehen O, Freyer G. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: The Lyon R-02-01 phase I trial. Clin Oncol 2008;20(5):369-374. Abstract ICI
Falandry C, You B, Morel-Soldner I, Bonnefoy M, Pujade-Lauraine E, Freyer G. Ovarian cancer in the elderly. Oncologie 2008;10(1):3-7
Boissel JP, Ribba B, Grenier E, Chapuisat G, Dronne MA. Modelling methodology in physiopathology. Progress Bioph Molecular Biol 2008;97(1):28-39. Abstract ICI
Billy F, Ol S, Morre-Trouithet H, Colin T, Bresch D, Ribba B, Grenier E. Multiscale mathematical model of tumoral angiogenesis and application of the efficiency analysis of anti-angiogenic treatments. Bull Cancer 2008;95:S65
Bekkal-Brikci F, Clairambault J, Ribba B, Perthame B. An age-and-cyclin-structured cell population model for healthy and tumoral tissues. J Math Biol 2008;57(1): 91-110. Abstract ICI
You B, Perrin P, Freyer G, Tranchand B, Ribba B, Henin E, Ruffion A, Trillet-Lenoir V, Girard P. A new approach: "PSA clearance" predicts biochemical relapse risk of patients with prostate cancer in the first month following radical prostatectomy. Fund Clin Pharmacol 2008;22(57S): 12
You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study. Lung Cancer 2008 ;62(2) :261-272. Abstract ICI
Tranchand B, Falandry C, You B, Girard P, Ribba B, Freyer G. Pharmacologie des agents anticancéreux chez le sujet âgé : une aide à l’adaptation des doses. Bull Cancer 2008:95(Supplément FMC n° 8):F21-F27
Tranchand B, Chabaud S, Colomban O, Dussart S, Pérol D. Design of Clinical Trials in Oncology. Lettre du Pharmacologue 2008;22(3):98-110
Tod M. Evaluation of drugs in pediatrics using K-PD models: perspectives. Fundam Clin Pharmacol 2008 Dec;22(6):589-594. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Hénin E, Trillet-Lenoir V, Tranchand B, Tod M, Girard P. Patient compliance estimated from pharmacokinetic sample: application to Imatinib. PAGE 17 (2008) Abstr 1363
Paule I, Tod M, Hénin E, You B, Tranchand B, Freyer G, Girard P. Model-based dose adaptation of capecitabine for prevention of severe hand-and-foot syndrome: in silico comparison with the standard method. PAGE 17 (2008) Abstr 1260
Ribba B, Chatel K, Tod M, Girard P, Freyer G, Tranchand B. Monolix benefits from external modules to manage complex ODE: Illustration with a population analysis of Irinotecan and its metabolites. PAGE 17 (2008) Abstr 1367
Abstracts ASCO (American Society of Clinical Oncology)
You B, Girard P, Freyer G, Tranchand B, Ruffion A, Paparel P, Devonec M, Henin E, Tod M, Perrin P. A new concept: PSA clearance predicts biochemical relapse risk of patients with prostate cancer in the first month following radical prostatectomy. ASCO Genitourinary Cancers Symposium Proceedings;2008 26: (20S):94
You B, Michallet A, Salles G, Casasnovas O, Tilly H,. Ribrag V, Sebban C, Falandry C, Tranchand B, FreyerG. Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). J Clin Oncol ASCO Annual Meeting Proceedings;2008 26: (20S):8537
Freyer G, Fumoleau P, You B, Isambert N, Chevalier P, Trillet Lenoir V. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol ASCO Annual Meeting Proceedings;2008 26:14539
Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol ASCO Annual Meeting Proceedings 2008;26:3599
Articles
Golfier F, Labrousse C, Frappart L Mathian B, Guastalla JP, Trillet-Lenoir V, Hajri T, Schott AM, Raudrant D. Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005. Gynécologie Obstétrique et Fertilité 2007;35 (3):205-215. Abstract ICI
Theis D, Gilleron V, Schott AM, Seguret F, Trillet-Lenoir V. An overview of the 2001-2002 cancer activity in the 30 French Regional and University Hospitals, based on PMSI data. Bull Cancer 2007;94(10):915-922. Abstract ICI
Falandry C, Bonnefoy M, You B, Freyer G. Metastatic prostate cancer treatment in the elderly. Bull Cancer. 2007;94 Suppl FMC:F89-96. Abstract ICI
Joerger M, Huitema A, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers HGJ, Twelves C, Beijnen JH, Schellens JHM. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG. Clin Pharmacokin. 2007;46(12):1051-1068. Abstract ICI
Dartois C, Brendel K, Comets E, Laffont C, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007;64(5):603-612. Abstract ICI
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res 2007;13(21):6410-6418. Abstract ICI
Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P. PROPHRE.75 Study Group. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007;64(4):428-438. Abstract ICI
Hénin E, You B, Tranchand B, Freyer G, Girard P. Issues of the study of patient compliance to treatment with oral anticancer chemotherapy: advantages of pharmacokinetic-pharmacodynamic modelisation. Thérapie 2007;62(2):77-85. Abstract ICI
Jacqmin P, Snoeck E, Van Schaick EA, Gieschke R, Pillai G, Steimer J-L, Girard P. Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K-PD Model. J Pharmacokin Pharmacodyn 2007; 34(1):57-85. Abstract ICI
Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46(3):221-234. Abstract ICI
Dartois C, Lemenuel-Diot A, Laveille C, Tranchand B, Tod M, Girard P. Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods. J Pharmacokinet Pharmacodyn 2007; 34(3):289-311. Abstract ICI
Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, Tranchand B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol 2007; 63:1-11. Abstract ICI
Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, Vermot-Desroches C, Tranchand B, Girard P. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clin Pharmacokinet 2007; 46(5):417-432. Abstract ICI
Gruwez B, Poirier MF, Dauphin A, Olie JP, Tod M. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine-lithium interaction. Contemp Clin Trials 2007; 28(3):276-287. Abstract ICI
Lichtman SM, Wildiers H, Chatelut E, Stiers C, Budman D, Morrison V, Tranchand B, Shapira I, Aapro M. International Society of Geriatric Oncology (SIOG) Chemotherapy Taskforce: Evaluation of chemotherapy in older patients. An analysis of the medical literature. J Clin Oncol 2007; 25(14):1832-1843. Abstract ICI
Tredan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E, Freyer G. Groupe D'investigateurs Nationaux Pour l'étude Des Cancers Ovariens. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 2007; 18(2):256-262. Abstract ICI
Tranchand B, Bruno R, Freyer G. Design of Phase I Studies in Oncology. In Ette EI and Williams PJ editors. Pharmacometrics: the Science of Quantitative Pharmacology. Wiley and Sons, Hoboken NJ USA, 2007
Abstracts PAGE (Population Approach Group in Europe)
You B, Perrin P, Paparel P, Freyer G, Colomban O, Tranchand B, Girard P. Kinetic models of PSA decrease after surgery in prostate tumor diseases as a help for clinician interpretation. PAGE 16 (2007) Abstr 1119
Ribba B, Tod M, Girard P, You B, Mercier C, Vassal G, Freyer G, Tranchand B. ODE solvers and stiffness issues for complex population PK models. PAGE 16 (2007) Abstr 1143
Delavenne X, Basset T, Girard P , Decousus H, Mismetti P, Laporte S. The use of an indirect response model to assess interaction between drugs: acenocoumarol and amoxicillin + clavulanic acid. PAGE 16 (2007) Abstr 1115
Hénin E, Trillet-Lenoir V, Colomban O, Tod M, Girard P. Estimation of patient compliance from pharmacokinetic samples. PAGE 16 (2007) Abstr 1193
Tod M, Blanchet B, Astier A, Hulin A. Steady-state Equation for the Bicompartmental Model with Gamma Absorption. Application to Mycophenolate PK in Renal Transplant Patients. PAGE 16 (2007) Abstr 1074
Abstracts ASCO (American Society of Clinical Oncology)
You B, Meille C, Barbolosi D, Tranchand B, Guitton J, Rioufol C, Iliadis A, Freyer G. A mechanistic model predicting hematopoiesis and tumor growth to optimize docetaxel + epirubicin (ET) administration in metastatic breast cancer (MBC): Phase I trial. J Clin Oncol ASCO Annual Meeting Proceedings;2007 25(18S):13013
Falandry C, You B, Milano G, Chatelut E, Rebischung C, Glehen O, Mille D, Delord J, Lledo G, Trillet-Lenoir V, Freyer G. Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings; 25(18S):2510
Articles
Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, Glehen O. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 2006; 32(6):597-601. Abstract ICI
Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, Monjanel-Mouterde S, Baciuchka-Palmaro M, Dupuis C, Yang C, Balti M, Lacarelle B, Duffaud F, Durand A, Favre R. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit 2006; 28(4):532-539. Abstract ICI
Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 2006; 28(2):212-218. Abstract ICI
Ribba B, Saut O, Colin T, Bresch D, Grenier E. Boissel JP. A multiscale mathematical model of a vascular tumor growth to predict the therapeutic bene.t of anti-invasive agents. J Theor Biol 2006; 243(4):532-541. Abstract ICI
Ribba B, Tracqui P, Boix JL, Boissel JP, Thomas SR. QxDB: A generic quantitative database to support mathematical modelling in biology. Phil Transact A Math Phys Eng Sci 2006; 364(1843):1517-1532. Abstract ICI
Ribba B, Colin T, Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor Biol Med Model 2006; 3:7. Abstract ICI
You B, Trillet-Lenoir V. Targeted therapies in oncology. Rev Med Interne. 2006 Dec;27S3:S285-S288
Boissel JP, Amsallem E, Kasparian C, Diallo M, Ribba B. Les traitements utilisés en cancérologie sont ils fondés sur des données de haut niveau de preuve ? Risque et Qualité, 2006 ; 3(2) :123-128
Freyer G, Braud AC, Vilela G, Zelek L. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the “observatory on elderly patients”. Ann Oncol 2006; 17(2):211-216. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Brendel K, Dartois C, Comets E, Laveille C, Lemmenuel-Diot A, Tranchand B, Girard P, Laffont C, Mentré F. Are population PK/PD models adequately evaluated? An exhaustive survey of the literature between 2002 and 2004. PAGE 15 (2006) Abstr 1009
Dartois C, Brendel K, Comets E, Laveille C, Laffont C, Tranchand B, Mentré F, Lemenuel-Diot A, Girard P. How is model building reported for population PK-PD? An exhaustive survey of the literature between 2002 and 2004. PAGE 15 (2006) Abstr 998
Hénin E, Zuideveld KP, Dartois C, Tranchand B, Freyer G, Girard P. A KPD Model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine. PAGE 15 (2006) Abstr 929
Claret, L, Girard P, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. A longitudinal model for tumor size measurements in clinical oncology studies. PAGE 15 (2006) Abstr 1004
Abstracts ASCO (American Society of Clinical Oncology)
Claret L, Girard P, O'Shaughnessy J, Hoff P, Van Cutsem E, Blum J, Zuideveld K, Jorga K, Fagerberg J, Bruno R. Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18S):6025
Salas S, Mercier C, Ciccolini J, Pourroy B, Dupuis C, Deville J, Baciuchka-Palmaro M, Durand A, Duffaud F, Tranchand B, Favre R. Population pharmacokinetic of total cisplatinum: Application to adaptative dosing with feed back in testicular cancer patient. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18S):2043
Freyer G, Debled M, Geay JF, Bachelot T, Blot E, Cretin J, Delozier T, Mille D, Ferrero JM, Romestaing P, Pujade-Lauraine E. Celecoxib (Ce) + exemestane (Ex) versus placebo + Ex in post-menopausal (PM) metastatic breast cancer (MBC) patients (pts): A double-blind phase III GINECO study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18S):565
Articles
Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M, Manchon M, Freyer G. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19(17):2419-2426. Abstract ICI
Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma. Ann Oncol 2005; 16(11):1795-1800. Abstract ICI
Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005; 96(3):228-234. Abstract ICI
Ribba B, Marron K, Agur Z, Alarcon T, Maini P. A mathematical model of Doxorubicin treatment efficacy on non-Hodgkin’s lymphoma: Investigation of current protocol through theoretical modelling result. Bull Math Biol 2005; 67(1):79-99. Abstract ICI
Gaujard S, Albrand G, Bonnefoy M, Courpron P, Freyer G. Le maniement des médicaments anticancéreux chez les malades âgés Press Med 2005 ; 34 :673-680. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Testart D, Girard P, Droz JP, Hénin E, Ardiet C, Zanetta S, Tranchand B. PK-PD model compared with K-PD model to predict haematotoxicity induced by anticancer drugs. PAGE 14 (2005) Abstr 695
Girard P, Mentré F. A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. PAGE 14 (2005) Abstr 834
Bergès A, Laporte S, Girard P, Epinat M , Zufferey P, Alamartine E, Decousus H, Mismetti P, for the PROPHRE-75 study Group. Do we need a perfect basic structural model before exploring the covariate model? Example with enoxaparin. PAGE 14 (2005) Abstr 790
Gruwez B, Tod M, Dauphin A. mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. PAGE 14 (2005) Abstr 698
Abstracts ASCO (American Society of Clinical Oncology)
Freyer G, Trédan O, Meille C, Barbolosi D, Tranchand B, Girard P, Iliadis A. Optimal duration of G-CSF prophylaxis after Docetaxel (D) + Epirubicin (E) in metastatic breast cancer (MBC): prediction using a mathematical model. J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16S):2044
Penault-Llorca F, Vincent-Salomon A, Mathieu MC, Trillet-Lenoir V, Khayat D, Marty M On Behalf Of The Esther Study Group. Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC). J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16S):764
Articles
Freyer G, Lortholary A, Delcambre C, Delozier T, Piot G, Genin F, Pujade-Lauraine E; Groupe D'investigateurs Nationaux Pour l’étude Des Cancers Ovariens. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breastcancer: the Gineco experience. Clin Oncol (R Coll Radiol). 2004; 16(1):17-23. Abstract ICI
Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004; 139(1):20-26. Abstract ICI
Girard P, Cucherat M, Guez D. Clinical trial simulation in drug development. Thérapie 2004; 59(3):287-304. Abstract ICI
Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Vallet PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glenhen O, Darnand P, Heilmann MO, Bleuse JP. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol 2004; 16(3):196-203. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Dartois C, Laveille C, Tranchand B, Tod M, Girard P. What is the Value of Uncertainty Parameter Estimates provided by Different Population PK Methods? PAGE 13 (2004) Abstr 475
Articles
Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G. Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0-04 Phase II Trial. J Clin Oncol 2003; 21(6):1119-1124. Abstract ICI
Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21(5):799-806. Abstract ICI
Sasco AJ, Merrill RM, Benhai M, Luzon V, Gerard , Freyer G. Trends in tobacco smoking among adolescents in Lyon, France. Eur J Cancer 2003; 39(4):496-504. Abstract ICI
Barbolosi D, Freyer G, Ciccolini J, Iliadis A. Dosage regimen optimization in cancer chemotherapy using a mathematical model. Bull Cancer 2003; 90(2):167-175. ICI
Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21(1):35-40. ICI
Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C,Tranchand B, Berger E, Lucas C, Guyotat D, Salles G, Coiffier B. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol 2003; 14(4), 615-622. Abstract ICI
Tranchand B, Laporte S, Glehen O, Freyer G. Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly.Crit Rev Oncol Hematol 2003; 48(2):199-214. Abstract ICI
Kastrissios H, Girard P. Protocol deviations and execution models. In: Ko HC, Duffull SB, editors. Simulation for Designing Clinical Trials. Marcel Dekker NY USA, 2003
Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10(8): 863-869. ICI
Clippe C, Freyer G, Milano G, Trillet-Lenoir V. Lethal toxicity of capecitabine due to abusive folic acid prescription? Clin Oncol 2003; 15(5):299-300.
Jaisson-Hot I, Schott AM, Clippe C, Ganne C, Hajri T, Poncet B, Trillet-Lenoir V, Colin C. Méthodes d’évaluation médico-économique. Applications à la Cancérologie Bull Cancer 2003 ; 90(11):939-945
Ganne C, Trillet-Lenoir V, Jaisson-Hot I, Clippe C, Heilmann MO, Hajri T, Poncet B, Heuclin C, Colin C. Quelles approches médico-économiques choisir pour l’évaluation de l’impact des molécules coûteuses en cancérologie Le modèle de l’Herceptin? dans le cancer du sein métastatique. Bull Cancer 2003 ; 90(11):955-960
Clippe C, Trillet-Lenoir V, Freyer G. Treatment of cancer : surgery, radiotherapy, chemotherapy, hormonotherapy. Multidisciplinary therapeutic decision making and informing the patient. Rev Prat 2003; 53(2):187-198.Review
Etienne–Mastroianni B, Freyer G, Cordier JF. Secondary lung cancers. Rev Prat 2003; 53(7):756-759. Review. Abstract ICI
Freyer G. Pharmacocinétique de population et prédiction de la toxicité hématologique des chimiothérapies. Oncologie 2003; 5:18-23
Girard P, Claret L, Ebling WF, Forgue S, Heathman M, Ghosh A, Benson CT. Qualification of an osteoporosis biomarker model for simulation. Clin Pharmacol Ther 2003; 73[2], 85
Abstracts PAGE (Population Approach Group in Europe)
Chanu P, Janoly-Dumenil A, Bleyzac N, Bourgeois J, Tranchand B. Pharmacokinetic model for vancomycin performed with sparse data on neonates. PAGE 12 (2003) Abstr 363
Girard P, Claret L, Ebling W, Forgue ST, Heathman M, Ghosh A, Benson CT. Evaluation Of An Osteoporosis Biomarker Model For Simulation Using Posterior Predictive Check Technique. PAGE 12 (2003) Abstr 460
Bourhis Y, Iliadis A, Lucas C, Depouilly AB, Laveille C, Tranchand B. Population Pharmacokinetic Study of Fotemustine. PAGE 12 (2003) Abstr 407
Abstracts ASCO (American Society of Clinical Oncology)
Mercier C, Tranchand B, Sicard E, Santos A, Vernillet L, Pein F, Doz F, Frappaz D, Mery Mignard D, Vassal G. Population pharmacokinetics of CPT-11 and its main metabolites in children: A NONMEM and Xpose covariates analysis. Proc Am Soc Clin Oncol 2003;22:529
Articles
Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz R, Gouttebel MC, Moindrot H, Boyer JD, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau JM, Hedelius F, Moraillon A, Chapuis F, Bleuse JP, Barbier Y, Heilmann MO, Valette PJ. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002; 75(899):903-908. Abstract ICI
Trillet-Lenoir V, Piedbois P, Buyse M. The role of colony stimulating factors in small cell lung cancer: why the question is still unsolved. Lung Cancer 2002; 37(2):125-126.
Schott AM, Hajri T, Colin C, Grateau F, Gilly FN, Tissot E, Couchoud C, Morestin C, Trillet-Lenoir V. Usefulness of the French DRG based information system (PMSI) in the measurement of cancer activity in a multidisciplinary hospital: the Hospices Civils de Lyon. Bull Cancer 2002; 89(11):969-973. Abstract ICI
Clippe C, Ligneau B, Trillet-Lenoir V. Rôle de la Gemcitabine dans le traitement des tumeurs malignes Bull Cancer 2002 ; 89:S 120-122. Abstract ICI
Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002; 94(9):2434-2440. Abstract ICI
Omezzine N, Khouatra C, Larive S, Freyer G, Isaac-Pinet S, Geriniere L, Droz JP, Souquet PJ. Rhabdomyosarcoma arising in mediastinal teratoma in an adult man: a case report. Ann Oncol 2002; 13(2):323-326. Review. Abstract ICI
Trillet-Lenoir V. Un bon « RUM" vaut mieux que deux « tu l’auras ». Editorial. Bull Cancer 2002; 89(11):991
Lansac J, Trillet-Lenoir V. Qui fait quoi en cancérologie en France ? Quelques réponses du PMSI. Info en santé 2002; 3:6-7
Clippe C, Freyer G, Bizollon MH, Raudrant D, Gilly F, Vitrey D, Ligneau B, Trillet-Lenoir V. Tumeurs malignes primitives du péritoine : étude d’une série de huit cas et revue de la littérature. Bull Cancer 2002; 89(4):430-436. Abstract ICI
Bonadona V, Saltel P, Desseigne F, Mignotte H, Saurin JC, Wang Q, Sinilnikova O, Giraud S, Freyer G, Plauchu H, Puisieux A, Lasset C. Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev 2002; 11(1):97-104. Abstract ICI
Freyer G, Hennebert P, Awada A, Gil T, Kerger J, Selleslags J, Brassinne C, Piccart M, De Valeriola D. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Clin Cancer Res 2002; 8(1):95-102. Abstract ICI
Nguyen L, Tranchand B, Puozzo C, Variol P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002; 53 (5):459-468. Abstract ICI
Variol P, Nguyen L, Tranchand B, Puozzo C. A simultaneous oral/iv population pharmacokinetic model for vinorelbine Eur J Clin Pharmacol 2002; 58:467-470. Abstract ICI
Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, Fouque D. Intermediate-dose (25mg/m²) IV melphalan for multiple myeloma with renal failure. J Nephrol 2002; 15(6):684-689. Abstract ICI
Chabaud S, Girard P, Nony P, Boissel JP. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29(4):339-363. Abstract ICI
Chaulet JF, Nony P, Bevalot F, Girard P, Chabaud S, Mounier C, Clair P, Boissel JP, Grelaud G. Bioequivalence evaluation of a fixed combination of chloroquine and proguanil in a capsule formulation versus a standard medication. Arzneimittelforschung 2002; 52(5):407-412. Abstract ICI
Duval V, Chabaud S, Girard P, Cucherat M, Hommel M, Boissel JP. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 22(8):1010-1018. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Tranchand B, Laporte S. Design and practical problems in population PK studies in the elderly. PAGE 11 (2002) Abstr 346
Chanu P, Tranchand B, Robert J. Population pharmacokinetics of epirubicin and its main metabolite epirubicinol using NONMEM. PAGE 11 (2002) Abstr 299
Hourcade-Potelleret F, Laveille C, Tod M, Jochemsen R. Mixture models: simulation and estimation with NONMEM. PAGE 11 (2002) Abstr 351
Tod M. Handling Concentrations Below Quantification Limit in Population. PAGE 11 (2002) Abstr 252
Abstracts ASCO (American Society of Clinical Oncology)
Freyer G, Le Rol A, Weber B, Provencal J, Ganem G, Jacquin J, Lavau-Denes S, Gisserot O, Flesch M, Paraiso D. GINECO Geriatric evaluation (GE) and feasibility of platin-based first-line chemotherapy in elderly patients with advanced ovarian cancer (AOC) Proc Am Soc Clin Oncol 2002; 21:1432
Gérard JP, Chapet O, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Freyer G. Oxaliplatin (OXA), fluorouracil (5-FU), I-leucovorin (I-LV) and radiotherapy (FolfoR 2) as preoperative treatment of advanced rectal cancer (ARC): the Lyon R0-04 phase II trial. Proc Am Soc Clin Oncol 2002; 21:581
Fumoleau P, Largillier R, Trillet-Lenoir V, Orfeuvre H, Extra JM, Dieras V, Berton-Rigaud D, Lesimple T, Culine S, Montestruc F, Mouri Z, Namer M. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: results of a large phase II study. Proc Am Soc Clin Oncol 2002; 21:247
Thèses et Post-Doc
Ongoing Pierrillas Philippe ...
2014 Wilbaux Mélanie Applications de la modélisation à l’analyse des cinétiques des marqueurs tumoraux sériques
2012 Sostelly Alexandre - Modélisation des intéractions entre chimiothérapies anticancéreuses et les inhibiteurs de transporteur d'efflux
2012 Gérard Cécile - Modèles PB-PK-PD de l'action des immunosupresseurs
2011 Paule Inès - Adaptation de posologie des médicaments anticancéreux sur la base des modèles longitudinaux à effets mixtes
2011 You Benoît - Dynamic analysis of serum tumor marker decline following anticancer treatment using population kinetic modeling approach
2009 Ternant David (Post doc) - Development of a drug – disease simulation model for rituximab in follicular non-Hodgkin lymphoma
2008 Hénin Emilie - Etude par la modélisation pharmacologique de la non-observance aux chimiothérapies anticancéreuses orales
2006 Dartois Céline - Validation des modèles PK/PD de population utilisés en oncologie
2006 Mercier Cédric - Apport de la pharmacologie de population pour l’adaptation des posologies en oncologie : application à 4 cytotoxiques
Rapports de Master
2013 Klervi Golhen - Etude pharmacocinétique d’un inhibiteur d’efflux en cours de développement :
MBLI-II-141
2013 Xue Yufeng - Utilisation de la fonction d’utilité : Optimisation du schéma posologie du sorafénib
2013 Gervais Frédéric - Méthodes de prédiction des interactions médicamenteuses: Vers une application en oncologie
2012 Quelin Arnaud - Comment les Thérapies Ciblées Anti-cancéreuses Interagissent ? Analyse à l'Aide d'un Modèle Semi-mécanistique de Structures Minimales de Voies de Signalisation
2011 Wilbaux Mélanie - Modélisation des cinétiques du CA 125 et de la taille tumorale dans la cancer ovarien
2010 Wilbaux Mélanie - Etude toxico-génomique de la relation dose-expression du 1,3 Dinitrobenzène, et détermination de Benchmark Doses
2010 Bonnefois Guillaume - Modélisation du pasage intracellulaire du sorafenib dans les cellules endothéliales
2010 Heudel Pierre - Paramètres de la radiorésistance et leurs applications en modélisation pour les lignées tumorales gliales
2009 Fontanilles Maxime - Modélisation de l’effet du bévacizumab sur les métastases hépatiques évalué par l’échographie dynamique de contraste
2009 Lignet Floriane - Modélisation de l’action d’un médicament anti-angiogénique aux niveaux moléculaire et cellulaire
2009 Sostelly Alexandre - Construction d’un modèle mécanistique pour la sécrétion, la distribution et l’élimination du PSA au cours de la phase de croissance et après prostatectomie radicale.
2008 Castellan Charlotte - Développement de modèles physiologiques pharmacocinétiques pour la prédiction de la distribution tissulaire de la vindésine
2008 Reda Lamnii Taha - Pharmacocinétique de l’irinotécan administré en chimiohyperthermie intrapéritonéale au cours du traitement des carcinoses péritonéales primitives et d’origine digestive
2008 Watkin Emmanuel - PROJET SILICOLON: Optimisation in silico de la chimiothérapie dans le cancer colorectal métastatique Etude préliminaire: Mise en place des techniques anatomopathologiques de validation des modèles chez la souris nude xénogreffée
2007 Paule Inès - Adaptation de la posologie de la capécitabine à l’aide d’un modèle longitudinal pour données catégorielles ordonnées
2007 Cotte Eddy - Etude pharmacocinétique de la mitomycine C et du cisplatine au cours des chimiohyperthermies intrapéritonéales pour traitement des carcinoses péritonéales d’origine ovarienne, primitive ou digestive
2007 You Benoît - Rôle pronostique de la cinétique de décroissance du PSA après prostatectomie radicale
2006 Colomban Olivier - Modèles de toxicité de l’irinotécan (CPT-11) et recherche de la Dose Maximale Tolérée par la méthode de réévaluation en continu (C.R.M)
2005 Colomban Olivier - Pharmacocinétique du Thiotépa administré à hautes doses chez l’enfant porteur de tumeurs réfractaires ou en rechute
2005 Testart Diane - Modélisation de l’hématotoxicité induite par les chimiothérapies anticancéreuses : Modèle pharmacocinétique et K-PD
Rapports d'internat
2009 Gérard Cécile - Prédiction de l’exposition tissulaire à la ciclosporine chez l’homme: utilisation d’un modèle physiologique
2007 Testart Diane - Modélisation pharmacocinétique du méthotrexate et du docétaxel. Un premier pas vers la gestion des toxicités
